TuesdaySep 20, 2022 10:38 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, will be releasing its financial report for fiscal year 2022, the period ended June 30, 2022, later this month. The company has announced that it will release the financial report, along with business highlights, on Sept. 23, 2022. In addition, the company has announced a conference call and webcast to be held the same day at 1 p.m. ET. Those interested in listening in on the conference call can register for the call; they will then receive information about how to dial in to the…

Continue Reading

FridaySep 16, 2022 2:10 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares of its common stock. According to the announcement, the combined offering price will be $6 per share (or common stock equivalent) and associated warrants. The company noted that in addition to the $6 per share exercise price, the warrants will be immediately exercisable with an…

Continue Reading

FridaySep 16, 2022 1:45 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (‘NBTS’) estimates that over 10,000 individuals with GBM succumb to the disease annually. GBM has a five-year survival rate of…

Continue Reading

FridaySep 16, 2022 1:26 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Leading Way in Scaling up Lidar for Mass-Market Deployments

Cepton (NASDAQ: CPTN) has, since its inception, sought to market the concept of “Lidar for Life,” introducing the use of lidar technology in mass-market consumer vehicles as well as the development of smart infrastructure in cities, spaces and industrial robotics. “As a pivotal part of its efforts in promoting lidar technology across different sectors, the company has invested in making lidar a truly scalable and accessible technology – cost efficient, reliable and easy to integrate into various systems,” a recent article reads. “Through its significant ADAS lidar series production award with Koito on the General Motors business, Cepton is leading…

Continue Reading

FridaySep 16, 2022 12:52 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Rides on Horizontal, Vertical Growth to Log Best Revenue Quarter Ever

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, has weathered the geopolitical drama and international upheaval that fueled recession concerns amid spiking inflation. None of that stopped the company from having its best revenue quarter ever, spearheaded by horizontal and vertical growth. “The Las Vegas-based company logged record revenues exceeding $9 million in the quarter, an improvement of approximately 177% from $3.25 million in the comparable quarter of fiscal 2021,” a recent article reads. “Meaningful progress in both its flagship business-to-business (‘B2B’) and new business-to-consumer (‘B2C’) divisions undergirded the jump in revenue.…

Continue Reading

ThursdaySep 15, 2022 2:55 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Secures Expanded Contract with Oregon-Based Client

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced that a locally owned, Oregon-based healthcare system has expanded its contract for its many facilities in the state. The announcement reads, “On the heels of securing a contract for a Knightscope K5 Autonomous Security Robot (‘ASR’), the new client has increased its order for an additional 2 K5 ASRs. The client has a children’s hospital, a 24-hour mental and behavioral health services center, and more than 70 primary care, specialty and urgent care clinics. The hospital’s goal is to deter criminal activity,…

Continue Reading

ThursdaySep 15, 2022 1:35 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a discussion of underlying logic-based evaluations that offer a realistic framework of expectations that investors can use in their analysis. “One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (‘FDA’), there are five steps to the drug development process: discovery and development, preclinical research, clinical research, FDA drug review, and,…

Continue Reading

ThursdaySep 15, 2022 12:30 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Provides First Look at Its Ultra-High-Performance FIVE RS

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced specifications and unveiled details on the FIVE RS - its ultra-high-performance EV sport crossover. The Mullen FIVE RS will be equipped with 800-volt architecture, all-wheel drive, a two-speed gearbox and over 1,000 horsepower and feature a top speed of 200 mph and acceleration from 0-60 mph in just 1.9 seconds. “From the inception of Mullen, it has been my mission to bring an ultra-high-performance EV to market,” said David Michery, CEO and chairman of Mullen Automotive. “The FIVE RS is intended to be one of the fastest vehicles…

Continue Reading

ThursdaySep 15, 2022 11:34 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Participation in H.C. Wainwright Global Investment Conference

Freight Technologies (NASDAQ: FRGT), a technology company developing solutions to optimize and automate the supply chain process as well as providing a platform for business-to-business (“B2B”) cross-border shipping in the United States/Mexico/Canada (“USMC”) region, will be presenting today at the H.C. Wainwright 24th Annual Global Investment Conference. Scheduled for Sept. 12–14, the three-day conference has been held in New York City as a hybrid event; participants have been attending both in person and online. Freight Technologies president Mike Flinker and CFO Paul Freudenthaler presented today, and their presentation will be available throughout the day for participants to view. To view…

Continue Reading

WednesdaySep 14, 2022 12:35 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a ‘may proceed’ letter and Investigational New Drug Application (‘IND’) clearance from the U.S.…

Continue Reading

Contact us: (512) 354-7000